Agios Pharmaceuticals (AGIO) Competitors

Agios Pharmaceuticals (NASDAQ:AGIO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Do analysts rate AGIO or JAZZ?

Agios Pharmaceuticals presently has a consensus price target of $52.33, suggesting a potential downside of 2.69%. Jazz Pharmaceuticals has a consensus price target of $175.00, suggesting a potential upside of 43.86%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the MarketBeat Community prefer AGIO or JAZZ?

Jazz Pharmaceuticals received 630 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 80.65% of users gave Jazz Pharmaceuticals an outperform vote while only 66.90% of users gave Agios Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Agios Pharmaceuticals	Outperform Votes 487 66.90%	Underperform Votes 241 33.10%
Jazz Pharmaceuticals	Outperform Votes 1117 80.65%	Underperform Votes 268 19.35%

Which has more volatility & risk, AGIO or JAZZ?

Agios Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Is AGIO or JAZZ more profitable?

Agios Pharmaceuticals has a net margin of 2,051.38% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	2,051.38%	-2.93%	-2.58%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Which has preferable earnings and valuation, AGIO or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$32.87M	93.31	-$352.09M	$11.36	4.73
Jazz Pharmaceuticals	$3.83B	1.92	$414.83M	$7.10	17.13

Does the media refer more to AGIO or JAZZ?

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 6 mentions for Agios Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.69 beat Agios Pharmaceuticals' score of 0.41 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of AGIO or JAZZ?

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.9% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Agios Pharmaceuticals on 13 of the 18 factors compared between the two stocks.